UNITED STATES
                SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C.  20549

                           FORM 10-QSB


[X]    QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
       ACT OF 1934

           For quarterly period ended:  March 31, 2002

[ ]    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
       EXCHANGE ACT OF 1934


                  Commission File No.  000-30991

             SKINOVATION PHARMACEUTICAL INCORPORATED
   (Name of small business issuer as specified in its charter)


        NEVADA                                             87-0458170
(State of incorporation)                (I. R. S. Employer Identification No.)

                        525 SOUTH 300 EAST
                    SALT LAKE CITY, UTAH 84111
                          (801) 323-2395
  (Address and telephone number of principal executive offices)


Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes [X]   No [ ]

As of May 1, 2002, the issuer had a total of 708,000 shares of common stock
issued and outstanding.

<PAGE>


                 PART I:   FINANCIAL INFORMATION


ITEM 1: FINANCIAL STATEMENTS

     The financial information set forth below with respect to our statements
of operations for the three month periods ended March 31, 2002 and 2001 is
unaudited.  This financial information, in the opinion of management, includes
all adjustments consisting of normal recurring entries necessary for the fair
presentation of such data.  The results of operations for the three months
ended March 31, 2002, are not necessarily indicative of results to be expected
for any subsequent period.




                                2
<PAGE>


                 Skinovation Pharmaceutical, Inc.
                       Financial Statements
                          March 31, 2002


<PAGE> 3


                 Skinovation Pharmaceutical, Inc.
                  (A Development Stage Company)
                          Balance Sheets


                              ASSETS
                                                      March 31,  December 31,
                                                        2002         2001
                                                   ------------- -------------
                                                    (Unaudited)

CURRENT ASSETS                                     $          -  $          -
                                                   ------------- -------------

  TOTAL ASSETS                                     $          -  $          -
                                                   ============= =============


               LIABILITIES AND STOCKHOLDER' EQUITY

CURRENT LIABILITIES

Accounts Payable - Related party                   $     28,776  $     28,776
                                                   ------------- -------------

  Total Liabilities                                      28,776        28,776
                                                   ------------- -------------

STOCKHOLDERS' EQUITY

Common Stock, $.001 par value; 50,000,000
  shares authorized; 708,000 shares
  issued and outstanding                                    708           708

Additional Paid in Capital                               25,148        25,148

Deficit Accumulated During the Development Stage        (54,632)      (54,632)
                                                   ------------- -------------

  Total Stockholders' Equity                            (28,776)      (28,776)
                                                   ------------- -------------

  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY       $          -  $          -
                                                   ============= =============

<PAGE> 4


                 Skinovation Pharmaceutical, Inc.
                  (A Development Stage Company)
                     Statement of Operations
                           (Unaudited)


                                                                 From
                                                                 inception on
                                     For the three For the three January 15,
                                     months ended  months ended  1988 to
                                     March 31,     March 31,     March 31,
                                     2002          2001          2002
                                     ------------- ------------- -------------

REVENUES                             $          -  $          -  $     27,937
                                     ------------- ------------- -------------
EXPENSES
  General & Administrative                      -             -       119,644
                                     ------------- ------------- -------------

    TOTAL EXPENSES                              -             -       119,644
                                     ------------- ------------- -------------
NET LOSS BEFORE DISCONTINUED
 OPERATIONS                                     -             -       (91,707)

GAIN ON DISPOSAL OF OPERATIONS                  -             -        37,075
                                     ------------- ------------- -------------

NET INCOME (LOSS)                    $          -  $          -  $    (54,632)
                                     ============= ============= =============

NET LOSS PER SHARE                   $          -  $          -  $      (0.12)
                                     ============= ============= =============

WEIGHTED AVERAGE SHARES OUTSTANDING       708,000       653,000       471,819
                                     ============= ============= =============



<PAGE> 5

                 Skinovation Pharmaceutical, Inc.
                   (A Development Stage Company)
                     Statement of Cash Flows
                           (Unaudited)


                                                                 From
                                                                 inception on
                                                                 January 15,
                                     For the three months ended  1988 through
                                               March 31,         March 31,
                                          2002          2001     2002
                                     ------------- ------------- -------------
Cash Flows from Operating Activities

  Net Loss                           $          -  $          -  $    (54,632)
  Less  Non-cash Items:
   Shares issued for services                   -             -        10,433
   Shares issued for debt payment               -             -         1,424
   Increase in accounts payable                 -             -        28,776
   Loss on disposal of PP&E                     -             -         5,263
                                     ------------- ------------- -------------
  Net Cash Provided (Used) by
   Operating Activities                         -             -        (8,736)
                                     ------------- ------------- -------------

Cash Flows from Investing Activities
  Cash paid for PP&E                            -             -        (5,264)
                                     ------------- ------------- -------------
  Net Cash Provided (Used) by
   Investing Activities                         -             -        (5,264)
                                     ------------- ------------- -------------

Cash Flows from Financing Activities
  Cash paid for offering costs                  -             -        (7,000)
  Common stock issued for cash                  -             -        21,000
                                     ------------- ------------- -------------
  Net Cash Provided (Used) by
    Financing Activities                        -             -        14,000
                                     ------------- ------------- -------------

Increase (Decrease) in Cash                     -             -             -

Cash and Cash Equivalents at
  Beginning of Period                           -             -             -
                                     ------------- ------------- -------------
Cash and Cash Equivalents at
  End of Period                      $          -  $          -  $          -
                                     ============= ============= =============
Supplemental Cash Flow Information:
  Stock issued for debt payment      $          -  $          -  $      1,424
  Stock issued for services          $          -  $          -  $     10,433
  Cash Paid For:
    Interest                         $          -  $          -  $          -
    Income Taxes                     $          -  $          -  $          -







<PAGE> 6



                 Skinovation Pharmaceutical, Inc.
                  (A Development Stage Company)
                Notes to the Financial Statements
                          March 31, 2002


GENERAL

Skinovation Pharmaceutical, Inc. (the Company) has elected to omit
substantially all footnotes to the financial statements for the three months
ended March 31, 2002 since there have been no material changes (other than
indicated in other footnotes) to the information previously reported by the
Company in their Annual Report filed on the Form 10-KSB for the twelve months
ended December 31, 2001.

UNAUDITED INFORMATION

The information furnished herein was taken from the books and records of the
Company without audit.  However, such information reflects all adjustments
which are, in the opinion of management, necessary to properly reflect the
results of the interim period presented.  The information presented is not
necessarily indicative of the results from operations expected for the full
fiscal year.


<PAGE> 7


     In this report references to "Skinovation," "we," "us," and "our" refer
to Skinovation Pharmaceutical Incorporated.

                    Forward Looking Statements

     This Form 10-QSB contains certain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.  For this
purpose any statements contained in this Form 10-QSB that are not statements
of historical fact may be deemed to be forward-looking statements.  Without
limiting the foregoing, words such as "may," "will," "expect," "believe,"
"anticipate," "estimate" or "continue" or comparable terminology are intended
to identify forward-looking statements.  These statements by their nature
involve substantial risks and uncertainties, and actual results may differ
materially depending on a variety of factors, many of which are not within
Skinovation's control.  These factors include but are not limited to economic
conditions generally and in the market which Skinovation may participate;
competition within Skinovation's chosen market and failure by Skinovation to
successfully develop business relationships.

ITEM 2:  PLAN OF OPERATIONS

     We are a development stage company with no assets, we have experienced
losses since our inception and we are dependent on financing to continue our
operations.  For the fiscal year ended December 31, 2001, and the three month
period ended March 31, 2002, we had no cash on hand and total current
liabilities of $28,776.  The $28,766 account payable is related to accounting
and legal fees paid on our behalf by a related party in fiscal year 1999.

     We have no commitments for capital expenditures for the next twelve
months.  During the next twelve months we believe that our current cash needs
may be met by loans from our directors, officers and stockholders.  However,
these understandings are not formal agreements and therefore these persons are
not obligated to provide funds.  We may repay any loans, costs of services and
advancements with cash, if available, or we may convert them into common
stock.  If we obtain a business opportunity, it may be necessary to raise
additional capital, which may be accomplished by selling our common stock.

     Our management intends to actively pursue business opportunities during
the next twelve months.  Based on current economic and regulatory conditions,
management believes that it is possible, if not probable, for a company like
ours, without many assets or liabilities, to negotiate a merger or acquisition
with a viable private company.  The opportunity arises principally because of
the high legal and accounting fees and the length of time associated with the
registration process of "going public."  However, should any of these
conditions change, it is very possible that there would be little or no
economic value for anyone taking over control of Skinovation.

     We have not made a formal study of the economic potential of any
business.  At the present, we have not identified any assets or business
opportunities for acquisition. All risks inherent in new and inexperienced
enterprises are inherent in our business.  Potential investors must recognize
that because of our limited capital available for investigation and
management's limited experience in business analysis we may not discover or
adequately evaluate adverse facts about the business opportunity to be
acquired.  Also, we intend to concentrate our acquisition efforts on
properties or businesses that we believe to be undervalued or that we believe
may realize a substantial benefit from being publicly owned.  Investors should
expect that any acquisition candidate may have little or no operating history,
or a history of losses or low profitability.

     It is emphasized that our management may effect transactions having a
potentially adverse impact upon our shareholders pursuant to the authority and
discretion of our management to complete acquisitions without submitting any
proposal to the stockholders for their consideration.

     Should a merger or acquisition prove unsuccessful, it is possible that we
may decide not to pursue further acquisition activities and management may
abandon its activities and our shares would become worthless.


PART II:  OTHER INFORMATION

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

(a)   Part II Exhibits

3.1     Articles of Incorporation as amended  (Incorporated by reference to
        exhibit 3.1 of the Form 10-KSB, filed March 29, 2002)

3.2     Bylaws of Skinovation (Incorporated by reference to exhibit 3.3 of the
        Form-SB, filed July 11, 2000)


(b)  Reports on Form 8-K

     None.



                            SIGNATURES

     In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.


                                   Skinovation Pharmaceutical Incorporated



                                    /s/ John W. Peters
Date 05/08/03                 By: ______________________________________
                                   John W. Peters, President and Director


                                9